Johnson & Johnson (JNJ)vsNewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
JNJ
Johnson & Johnson
$275.19
+1.53%
HEALTHCARE · Cap: $615.87B
NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares
$21.07
+2.78%
HEALTHCARE · Cap: $2.37B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 1394859% more annual revenue ($99.33B vs $7.12M). JNJ leads profitability with a 16.2% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
NAMS
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$275.19
$131.07 premium
Intrinsic value data unavailable for NAMS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -32.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : NAMS
The strongest argument for NAMS centers on Debt/Equity, Altman Z-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : NAMS
The primary concerns for NAMS are EPS Growth, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while NAMS is a value play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.21 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 24/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →NewAmsterdam Pharma Company N.V. Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
NewAmsterdam Pharma Company N.V. is a forward-looking biotechnology firm focused on the development of innovative therapies for cardiometabolic diseases, leveraging its proprietary technology platform to address critical unmet medical needs. With an advanced clinical development pipeline and a strategic commitment to reshaping treatment approaches, the company stands poised to significantly influence the healthcare landscape. Guided by a seasoned management team, NewAmsterdam offers a compelling investment opportunity for institutional investors aimed at facilitating transformative healthcare solutions that enhance patient outcomes while ensuring sustainable growth in the biopharmaceutical arena.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?